المؤلفون: Chorão, Pedro, Henriques, Marta, Villalba, Marta, Montoro, Juan, Balaguer-Roselló, Aitana, González, Eva María, Gómez, María Dolores, Gómez, Inés, Solves, Pilar, Santiago, Marta, Asensi, Pedro, Lamas, Brais, Bataller, Ana, Granados, Pablo, Eiris, Juan, Martínez, David, Louro, Alberto, Rebollar, Paula, Perla, Aurora, Salavert, Miguel, de la Rubia, Javier, Sanz, Miguel Ángel, Sanz, Jaime

المصدر: Transplantation and Cellular Therapy; May 2024, Vol. 30 Issue: 5 p538.e1-538.e10, 48430p

مستخلص: • First CMV reactivations in HSCT with PTCy without letermovir prophylaxis occurred in 46% of patients.• The reactivation rate was 73% for CMV seropositive recipients and 49% for CMV-seropositive donors.• Risk factors for reactivation were CMV seropositivity, haploidentical HSCT, older patient, and grade II-IV acute GVHD.• Second and third CMV reactivations occurred in 13% and 4.4% of patients, independent of donor type.

المؤلفون: Fernandez, Miguel A., Korutcheva, Elka, de la Rubia, Javier

المصدر: Physica A 462 (2016) 603-618

مصطلحات موضوعية: Physics - Physics and Society, Condensed Matter - Statistical Mechanics, 82B44

الوصف: We study a diluted Blume-Capel model of 3-state sites as an attempt to understand how some social processes as cooperation or organization happen. For this aim we study the effect of the complex network topology on the equilibrium properties of the model, by focusing on three different substrates: random graph, Watts-Strogatz and Newman substrates.
Comment: 16 pages, 11 figures

الوصول الحر: http://arxiv.org/abs/1507.05111Test

المؤلفون: Sanz, Miguel Ángel, Montoro, Juan, Balaguer-Roselló, Aitana, Chorão, Pedro, Villalba, Marta, Gómez, Inés, Solves, Pilar, Santiago, Marta, Asensi, Pedro, Lamas, Brais, Bataller, Ana, Granados, Pablo, Eiris, Juan, Martinez, David, Lloret, Pilar, Louro, Alberto, Rebollar, Paula, Perla, Aurora, de la Rubia, Javier, Sanz, Jaime

المصدر: Bone Marrow Transplant ; ISSN:1476-5365

الوصف: This 45-year study (1978-2022) at a single institution evaluated HSCT outcomes and complications, emphasizing recent advances, with to provide insights into HSCT's evolving field and ongoing efforts to enhance patient outcomes. Involving 1707 patients, the study revealed an initial phase (1978-1987) with a limited activity that yielded modest outcomes, a nearly three-decade span (1988-2016) with a substantial increase in transplant activity, emphasizing umbilical cord blood transplantation (UCBT) for patients lacking a suitable matched sibling donor. In addition to a gradual increase in recipient age, significant improvement in outcomes emerged in the recent period (2017-2022), marked by UCBT replacement with haploidentical transplants, introduction of PTCY-based GVHD prophylaxis for all type of transplants, and increased use of conditioning regimens with thiotepa, busulfan, and fludarabine. In this period, reductions in GVHD, non-relapse mortality, and relapse rates significantly contributed to improved overall survival, event-free survival, and GVHD-free/relapse-free survival. The study identified specific factors, including GVHD prophylaxis and donor selection changes, associated with these positive trends. This four-decade study provides a unique perspective on allogeneic HSCT, showcasing the dynamic evolution of transplantation practices and their impact on outcomes, offering valuable insights for personalized treatment approaches and emphasizing continual innovation in this critical therapeutic modality.

العلاقة: https://doi.org/10.1038/s41409-024-02319-xTest; https://pubmed.ncbi.nlm.nih.gov/38918495Test

الإتاحة: https://doi.org/10.1038/s41409-024-02319-xTest
https://pubmed.ncbi.nlm.nih.gov/38918495Test

المؤلفون: Seguí, Inés Gómez, Mingot Castellano, María Eva, Izquierdo, Cristina Pascual, de la Rubia, Javier

المصدر: Expert Review of Hematology ; volume 17, issue 1-3, page 9-25 ; ISSN 1747-4086 1747-4094

الإتاحة: https://doi.org/10.1080/17474086.2024.2318347Test

المؤلفون: Scully, Marie, de la Rubia, Javier, Pavenski, Katerina, Metjian, Ara, Knöbl, Paul, Peyvandi, Flora, Cataland, Spero, Coppo, Paul, Kremer Hovinga, Johanna A, Minkue Mi Edou, Jessica, De Passos Sousa, Rui, Callewaert, Filip, Gunawardena, Sriya, Lin, Julie

المصدر: Scully, Marie; de la Rubia, Javier; Pavenski, Katerina; Metjian, Ara; Knöbl, Paul; Peyvandi, Flora; Cataland, Spero; Coppo, Paul; Kremer Hovinga, Johanna A; Minkue Mi Edou, Jessica; De Passos Sousa, Rui; Callewaert, Filip; Gunawardena, Sriya; Lin, Julie (2022). Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. Journal of thrombosis and haemostasis, 20(12), pp. 2810-2822. Wiley-Blackwell 10.1111/jth.15892

مصطلحات موضوعية: 610 Medicine & health, 340 Law

الوصف: INTRODUCTION Caplacizumab demonstrated efficacy and safety in patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in the Phase 3 HERCULES trial. However, data on long-term outcomes following caplacizumab treatment are limited. OBJECTIVES The post-HERCULES trial (NCT02878603) evaluated long-term outcomes of patients with iTTP treated with caplacizumab in HERCULES and safety and efficacy of repeated caplacizumab use. PATIENTS/METHODS Over 3 years' follow-up, patients could receive open-label caplacizumab with therapeutic plasma exchange (TPE) and immunosuppressive therapy (IST) in case of recurrence. Adverse events (AEs) were assessed during the overall study period (intention-to-observe [ITO] population) and during recurrences (recurrence population). TTP-related events (TTP-related death, recurrence, major thromboembolic events) were assessed in the efficacy ITO population (patients without recurrence during HERCULES or before post-HERCULES). RESULTS Among 104 enrolled patients, incidences of AEs and serious AEs were similar between patients who had received caplacizumab+TPE+IST during HERCULES (n=75) and those treated with placebo+TPE+IST (placebo; n=29). TTP-related events occurred in 8% of patients (4/49) randomized to caplacizumab during HERCULES versus 38% (11/29) randomized to placebo. Nineteen patients had ≥1 recurrence; 13 of these were treated with caplacizumab. First recurrence episode was resolved or resolving for all patients treated with caplacizumab, including 9 patients with repeat caplacizumab use. All second recurrences (6/6) were resolved. Safety profile of caplacizumab for treatment of recurrence was consistent with HERCULES; most bleeding events were non-serious. No major cases of organ dysfunction were observed. CONCLUSIONS Long-term follow-up supports the safety and efficacy of caplacizumab for iTTP and its repeated use for recurrences.

وصف الملف: application/pdf

العلاقة: https://boris.unibe.ch/173249Test/

الإتاحة: https://doi.org/10.1111/jth.15892Test
https://boris.unibe.ch/173249/1/J_of_Thrombosis_Haemost_-_2022_-_Scully_-_Long_term_follow_up_of_patients_treated_with_caplacizumab_and_safety_and_efficacy.pdfTest
https://boris.unibe.ch/173249Test/

المؤلفون: Puig, Noemí, Contreras, María Teresa, Agulló, Cristina, Martínez López, Joaquín, Oriol Bosch, Albert, Blanchard, María Jesús, Ríos, Rafael, Martín, Jesús, Iñigo, María Belén, Sureda, Anna, Hernández, Miguel Teodoro, De La Rubia, Javier, González Calle, Verónica, Krsnik, Isabel, Cabañas, Valentín, Palomera, Luis, Moraleda, José María, Bargay, Joan, Cedena, María Teresa, Paiva, Bruno, Rosiñol, Laura, Bladé, J. (Joan), San Miguel, Jesús, Lahuerta, Juan José, Mateos, María Victoria

المصدر: Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

مصطلحات موضوعية: Anticossos monoclonals, Espectrometria de masses, Monoclonal antibodies

الوصف: Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), and after induction (n = 183), autologous stem cell transplantation (n = 173), and consolidation (n = 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in >80% of cases, being most discordances due to EXENT&FLC-MS+ but IFE cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P = .0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome.

وصف الملف: 6 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2021006762Test; Blood Advances, 2022, vol. 6, núm. 11, p. 3234-3239; https://doi.org/10.1182/bloodadvances.2021006762Test; http://hdl.handle.net/2445/188952Test; 9298490

الإتاحة: https://doi.org/10.1182/bloodadvances.2021006762Test
http://hdl.handle.net/2445/188952Test

المؤلفون: Pascual, Cristina, Mingot-Castellano, María Eva, Kerguelen Fuentes, Ana E., García-Arroba, José, Cid, Joan, Jimenez, Moraima, Valcárcel, David, Gómez-Seguí, Inés, de la Rubia, Javier, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García-Muñoz, Nadia, Vara, Míriam, Fernández-Zarzoso, Miguel, García-Candel, Faustino, Paciello, María Liz, García-García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Vidan, Julia, Moreno-Jiménez, Gemma, López Lorenzo, José Luis, González Arias, Elena, Freiría, Carmen, Solé, María, Ãvila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez-Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juan Ramón, Salinas, Ramón, del Rio-Garma, Julio

الوصف: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P <.05) and less refractoriness (4.5% vs 14.1%; P <.05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P <.05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P <.001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX.

وصف الملف: application/pdf

العلاقة: Blood advances; Vol. 6 Núm. 24 (December 2022), p. 6219-6227; https://ddd.uab.cat/record/282297Test; urn:10.1182/bloodadvances.2022008028; urn:oai:ddd.uab.cat:282297; urn:scopus_id:85141669213; urn:articleid:24739537v6n24p6219; urn:pmid:35930694; urn:pmc-uid:9792393; urn:pmcid:PMC9792393; urn:oai:pubmedcentral.nih.gov:9792393

الإتاحة: https://ddd.uab.cat/record/282297Test

المؤلفون: Encinas, Cristina, Hernandez-Rivas, José-Ãngel, Oriol, Albert, Rosiñol, Laura, Blanchard, María Jesús, Bellón, José-María, García-Sanz, Ramón, de la Rubia, Javier, López de la Guía, Ana, Jímenez-Ubieto, Ana, Jarque, Isidro, Iñigo, Belén, Dourdil, Victoria, De Arriba, Felipe, Cuéllar Pérez-Ãvila, Clara, Gonzalez, Yolanda, Hernández, Miguel-Teodoro, Bargay, Joan, Granell, Miquel, Rodríguez-Otero, Paula, Silvent, Maialen, Cabrera, Carmen, Rios, Rafael, Alegre, Adrián, Gironella, Mercedes, Gonzalez, Marta-Sonia, Sureda, Anna, Sampol, Antonia, Ocio, Enrique M., Krsnik, Isabel, García, Antonio, García-Mateo, Aránzazu, Soler, Joan-Alfons, Martín Sánchez, Jesús, Arguiñano, José M, Mateos, M. V., Bladé Creixenti, Juan, San-Miguel, J, Lahuerta, J. J, Martínez-López, Joaquín

مصطلحات موضوعية: Antibiotic Prophylaxis, Humans, Male, Multiple Myeloma

الوصف: Altres ajuts: PETHEMA (Spanish Program for the Treatment of Hematological Diseases), Madrid, Spain ; Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. We undertook a post hoc analysis of infections in four clinical trials from the Spanish Myeloma Group, involving a total of 1347 patients (847 transplant candidates). Regarding the GEM2010 > 65 trial, antibiotic prophylaxis was mandatory, so we excluded it from the final analysis. The incidence of severe infection episodes within the first 6 months was 13.8%, and majority of the patients experiencing the first episode before 4 months (11.1%). 1.2% of patients died because of infections within the first 6 months (1% before 4 months). Variables associated with increased risk of severe infection in the first 4 months included serum albumin ≤30 g/L, ECOG > 1, male sex, and non-IgA type MM. A simple risk score with these variables facilitated the identification of three risk groups with different probabilities of severe infection within the first 4 months: low-risk (score 0-2) 8.2%; intermediate-risk (score 3) 19.2%; and high-risk (score 4) 28.3%. Patients with intermediate/high risk could be candidates for prophylactic antibiotic therapies.

وصف الملف: application/pdf

العلاقة: Blood Cancer Journal; Vol. 12 Núm. 4 (april 2022), p. 68; https://ddd.uab.cat/record/280855Test; urn:10.1038/s41408-022-00652-2; urn:oai:ddd.uab.cat:280855; urn:scopus_id:85128796138; urn:articleid:20445385v12n4p68; urn:pmid:35440057; urn:pmc-uid:9018751; urn:pmcid:PMC9018751; urn:oai:pubmedcentral.nih.gov:9018751

الإتاحة: https://ddd.uab.cat/record/280855Test

المؤلفون: Mosquera Orgueira, Adrian, González Pérez, Marta Sonia, Diaz Arias, José, Rosiñol, Laura, Oriol, Albert, Teruel, Ana Isabel, Martínez-López, Joaquín, Palomera, Luis, Granell, Miquel, Blanchard, María Jesús, de la Rubia, Javier, López de la Guia, Ana, Ríos-Tamayo, Rafael, Sureda, Anna, Hernández, Miguel Teodoro, Bengoechea, Enrique, Calasanz, M.J, Gutierrez, Norma, Martin, María Luís, Bladé Creixenti, Juan, Lahuerta, J. J, San-Miguel, J, Mateos, M. V, Universitat Autònoma de Barcelona

مصطلحات موضوعية: Humans, Multiple Myeloma, Neoplasm Staging, Prognosis, Risk Assessment, Unsupervised Machine Learning

وصف الملف: application/pdf

العلاقة: Blood Cancer Journal; Vol. 12 Núm. 4 (april 2022), p. 76; https://ddd.uab.cat/record/270545Test; urn:10.1038/s41408-022-00647-z; urn:oai:ddd.uab.cat:270545; urn:scopus_id:85128861737; urn:articleid:20445385v12n4p76; urn:pmid:35468898; urn:pmc-uid:9038663; urn:pmcid:PMC9038663; urn:oai:pubmedcentral.nih.gov:9038663

الإتاحة: https://ddd.uab.cat/record/270545Test

المؤلفون: Dimopoulos, Meletios A., Moreau, Philippe, Augustson, Bradley, Castro, Nelson, Pika, Tomas, Delimpasi, Sosana, De la Rubia, Javier, Maiolino, Angelo, Reiman, Tony, Martinez‐Lopez, Joaquin, Martin, Thomas, Mikhael, Joseph, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaelle, Marion, Sylvia, Hajek, Roman

المساهمون: Sanofi

المصدر: American Journal of Hematology ; volume 98, issue 1 ; ISSN 0361-8609 1096-8652

الإتاحة: https://doi.org/10.1002/ajh.26602Test